For the quarter ending 2026-03-31, UNCY has $64,406K in assets. $26,702K in debts. $37,371K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 37,371 | 29,198 | 42,695 | 22,327 |
| Prepaid expenses and other current assets | 8,959 | 7,692 | 7,592 | 7,199 |
| Marketable securities | 17,215 | 12,071 | - | - |
| Total current assets | 63,545 | 48,961 | 50,287 | 29,526 |
| Right of use asset, net | 813 | 108 | 249 | 386 |
| Subtotal | 106 | 138 | 138 | - |
| Less accumulated depreciation | 58 | 72 | 63 | - |
| Property and equipment, net | 48 | 66 | 75 | 83 |
| Total assets | 64,406 | 49,135 | 50,611 | 29,995 |
| Accounts payable | 1,140 | 383 | 957 | 775 |
| Accrued liabilities | 3,052 | 1,523 | 2,762 | 2,168 |
| Warrant liability | 21,695 | 16,915 | 9,147 | 10,214 |
| Operating lease liability - current | 598 | 117 | 265 | 409 |
| Preferred stock, value-Series A2Preferred Stock | - | - | 0 | 0 |
| Total current liabilities | 26,485 | 18,938 | 13,131 | 13,566 |
| Preferred stock, value-Series B2Preferred Stock | - | - | 0 | 0 |
| Operating lease liability long term | 217 | - | 0 | 0 |
| Preferred stock, value | - | - | 0 | 0 |
| Total liabilities | 26,702 | 18,938 | 13,131 | 13,566 |
| Common stock, 0.001 par value per share 400,000,000 shares authorized at december 31, 2025, and march 31, 2026 22,114,245 and 25,237,782 shares issued and outstanding at december 31, 2025, and march 31, 2026, respectively | 25 | 22 | 21 | 122 |
| Accumulated other comprehensive (loss) income | 6 | -1 | - | - |
| Additional paid-in capital | 178,321 | 158,001 | 150,617 | 123,454 |
| Accumulated deficit | -140,648 | -127,825 | -113,158 | -107,147 |
| Total stockholders equity | 37,704 | 30,197 | 37,480 | 16,429 |
| Total liabilities and stockholders equity | 64,406 | 49,135 | 50,611 | 29,995 |
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)